RIGL

Rigel Pharmaceuticals Inc. (New)

39.65

USD

-6.06

-13.26%

Nov 06, 15:59 UTC -5

Closed

After-Market

39.59

-0.05

-0.14%

Rigel Pharmaceuticals Inc. (New) (RIGL) Earnings

RIGL Earnings Reports

Positive Surprise Ratio

RIGL beat 31 of 44 last estimates.

70%

Next Report

Date of Next Report

Mar 01, 2027

Estimate for Q4 26 (Revenue/ EPS)

$90.47M

$0.90

Implied change from Q3 26 (Revenue/ EPS)

+11.84%

+38.46%

Implied change from Q4 25 (Revenue/ EPS)

+29.61%

-21.05%

Rigel Pharmaceuticals Inc. (New) earnings per share and revenue

On Nov 05, 2026, RIGL reported earnings of 0.65 USD per share (EPS) for Q3 26, missing the estimate of 0.85 USD, resulting in a -23.83% surprise. Revenue reached 80.89 million, compared to an expected 81.70 million, with a -0.99% difference. The market reacted with a -13.26% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of 0.90 USD, with revenue projected to reach 90.47 million USD, implying an increase of 38.46% EPS, and increase of 11.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

FAQ

What were Rigel Pharmaceuticals Inc. (New)'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Rigel Pharmaceuticals Inc. (New) reported EPS of $0.65, missing estimates by -23.83%, and revenue of $80.89M, -0.99% below expectations.

How did the market react to Rigel Pharmaceuticals Inc. (New)'s Q3 2026 earnings?

The stock price moved down -13.26%, changed from $45.71 before the earnings release to $39.65 the day after.

When is Rigel Pharmaceuticals Inc. (New) expected to report next?

The next earning report is scheduled for Mar 01, 2027.

What are the forecasts for Rigel Pharmaceuticals Inc. (New)'s next earnings report?

Based on -- analysts, Rigel Pharmaceuticals Inc. (New) is expected to report EPS of $0.90 and revenue of $90.47M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.